Analysts forecast that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will report earnings of ($0.24) per share for the current quarter, Zacks reports. Three analysts have made estimates for Dicerna Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.13). Dicerna Pharmaceuticals reported earnings per share of ($0.92) in the same quarter last year, which indicates a positive year-over-year growth rate of 73.9%. The firm is scheduled to announce its next earnings report on Thursday, November 1st.
Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.26). The company had revenue of $1.55 million during the quarter, compared to analysts’ expectations of $1.79 million. Dicerna Pharmaceuticals had a negative return on equity of 97.39% and a negative net margin of 1,642.81%.
DRNA has been the subject of a number of analyst reports. Stifel Nicolaus upped their price target on Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. BidaskClub cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 8th. B. Riley increased their target price on Dicerna Pharmaceuticals from $10.00 to $13.50 and gave the company a “neutral” rating in a research note on Monday. Citigroup assumed coverage on Dicerna Pharmaceuticals in a research note on Thursday, September 13th. They set a “buy” rating and a $27.00 target price for the company. Finally, Chardan Capital reiterated a “hold” rating and set a $14.50 target price on shares of Dicerna Pharmaceuticals in a research note on Monday, August 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Dicerna Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $17.41.
NASDAQ DRNA opened at $16.80 on Tuesday. Dicerna Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $17.98. The company has a quick ratio of 5.40, a current ratio of 5.40 and a debt-to-equity ratio of 0.14.
In related news, Director Dennis Langer sold 14,531 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $16.00, for a total transaction of $232,496.00. Following the sale, the director now directly owns 29,064 shares of the company’s stock, valued at approximately $465,024. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider James B. Weissman sold 2,301 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $17.50, for a total value of $40,267.50. Following the sale, the insider now directly owns 26,781 shares in the company, valued at $468,667.50. The disclosure for this sale can be found here. Corporate insiders own 19.85% of the company’s stock.
Several hedge funds have recently bought and sold shares of DRNA. BlackRock Inc. raised its position in shares of Dicerna Pharmaceuticals by 839.8% during the 2nd quarter. BlackRock Inc. now owns 2,607,895 shares of the biopharmaceutical company’s stock valued at $31,946,000 after acquiring an additional 2,330,402 shares in the last quarter. Emerald Advisers Inc. PA raised its position in shares of Dicerna Pharmaceuticals by 2,002.5% during the 2nd quarter. Emerald Advisers Inc. PA now owns 603,508 shares of the biopharmaceutical company’s stock valued at $7,393,000 after acquiring an additional 574,804 shares in the last quarter. Northern Trust Corp raised its position in shares of Dicerna Pharmaceuticals by 719.5% during the 2nd quarter. Northern Trust Corp now owns 486,668 shares of the biopharmaceutical company’s stock valued at $5,962,000 after acquiring an additional 427,284 shares in the last quarter. Artal Group S.A. acquired a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter valued at approximately $4,063,000. Finally, Emerald Mutual Fund Advisers Trust raised its position in shares of Dicerna Pharmaceuticals by 247.6% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 526,859 shares of the biopharmaceutical company’s stock valued at $6,454,000 after acquiring an additional 375,288 shares in the last quarter. 87.02% of the stock is currently owned by institutional investors and hedge funds.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Further Reading: Beta
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.